Experts Say Interpretable Results Unlikely In Burzynski’s Antineoplastons Studies
Special Report: Politicla Pressure, System Loopholes, Enabled Burzynski To Avoid Usuals
Scientific Process
“Unfortunate Result Of Burzynski’s Practice Over Two Decades: Thousands Of Patients, Not Enough Data” To Determine Safety, Efficacy, FDA Says
Reviewers Note Major Flaws In Design Of Burzynski’s Trials
Interview: Burzynski Explains Why He Calls Treatment “Non-Toxic”
Case Study: The Post-Surgical Treatment Of A Child With Medulloblastoma At The Burzynski Clinic
Trending Stories
- Cancer clinical trials shouldn’t discriminate—but they do
- Mount Sinai oncologist Krystal Cascetta, 40, and her infant daughter die in Somers, NY, home
- Undergrad intern at MSK poses a profound question: What if Henrietta Lacks had a Black doctor?
- In the aftermath of Helene and Milton, oncologists resort to airlifts to keep treatments on schedule
Helene knocks out Baxter facility, creating shortage of IV fluids - ACS board member Wayne Frederick steps in as interim CEO, replacing Karen Knudsen
National search will be conducted - Latino oncology leaders discuss representation in clinical trials, translational research, and health care
Mesa, Carvajal-Carmona, Cruz-Correa, Perez, Ramirez, Sanchez: “We’re here to help lead and collaborate.”